Search

Search Constraints

You searched for: Author/Creator Marks, David I.

Search Results

2. At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial. (27th March 2020)

3. Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment. (22nd August 2019)

4. Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. Issue 11 (22nd August 2016)

5. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Issue 19 (17th June 2016)

6. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant. Issue 2 (26th August 2016)

7. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia. Issue 6 (24th November 2020)

8. Graft‐versus‐host disease induced by tisagenlecleucel in patients after allogeneic stem cell transplantation. (28th July 2021)

9. Guidelines on the management and admission to intensive care of critically ill adult patients with haematological malignancy in the UK. (19th August 2015)

10. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. Issue 16 (4th May 2017)